IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference

IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference

IDEXX Laboratories (NASDAQ:IDXX) executives reiterated the company’s long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product innovation, commercial investments and recurring-revenue economics as key drivers. Chief Executive Of

IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets

Key Points Interested in IDEXX Laboratories, Inc.? Here are five stocks we like better. IDEXX reaffirmed its long-term growth targets of more than 10% organic revenue growth and more than 15% EPS growth, supported by recurring-revenue momentum and a large, underpenetrated veterinary…